Research programme: monoclonal antibodies - Genor Biopharma

Drug Profile

Research programme: monoclonal antibodies - Genor Biopharma

Alternative Names: GB 214; GB 223; GB 235; GB 251

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genor Biopharma
  • Developer Genor Biopharma; Unknown
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Metabolic disorders

Most Recent Events

  • 20 Apr 2017 Shanghai Food and Drug Administration grants Notice of Acceptance for an IND application for GB 223 for metabolic disorders in China (Genor BioPharma pipeline, July 2017 )
  • 14 Apr 2017 Genor BioPharma files an IND application for GB 251 with the Shanghai Food and Drug Administration in China
  • 03 Mar 2017 Genor BioPharma files an IND application for GB 235 with the Shanghai Food and Drug Administration in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top